Sophia Bioscience Inc

Biotech · Private

Liver-targeted histone deacetylase inhibitor molecules for hepatocellular carcinoma treatment

Grants
$600K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of Novel Targeted Therapy for Hepatocellular Carcinoma$300,000
Federal grantDepartment of Health and Human Services · Phase I · Development of Novel Targeted Therapy for Hepatocellular Carcinoma$300,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2877DELINEATE INC——
2878SPECTRAL THERAPEUTICS, INC.——
2879CYPRESS BIOPHARMA, INC.——
2880Sophia Bioscience Inc——
2881CG Oncology——
2882LABORECOM THERAPEUTICS INC.——
2883BIOCOGNON LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 2
  • Hydantoin-derived Histone Deacetylase (hdac) Inhibitors And Methods Of Making And Using Thereofapplication
  • Hydantoin-derived Histone Deacetylase (hdac) Inhibitors And Methods Of Making And Using Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.